Company: FEAV
Filing Date: 2025-08-25
Form Type: 424B5
Source: 0001888654-25-000019
Chunk: 10

Company: 5E Advanced Materials, Inc.
Filing Date: 2025-08-25
Form: 424B5
Chunk 10
---
-up agreements                                 |     | We, and our officers and directors have agreed with the underwriter, subject to certain exceptions, for a period of 90 days following the closing of this offering, not to sell, transfer or otherwise dispose of, directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of capital stock for such applicable period. See “Underwriting.”                                                                                                                                                                                                                                                                                                               |
| Market for common stock                            |     | Our common stock is listed on Nasdaq under the symbol “FEAM”. Our CDIs are listed on the ASX under the symbol “5EA” with ten CDIs representing an interest in one share of our common stock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

The number of shares of common stock to be outstanding after this offering is based on 20,066,779 shares of our common stock outstanding as of August 20, 2025 and excludes: • 647 thousand options outstanding as of August 20, 2025, with a weighted-average exercise price of $18.31 per share; • 33 thousand restricted share and performance share awards (“Awards”) outstanding as of August 20, 2025; and • 6,096,465 shares of common stock issuable upon exercise of warrants outstanding as of August 20, 2025, at a weighted average exercise price of $4.6770 per share. Except as otherwise indicated, all information in this prospectus supplement assumes: • no exercise of outstanding options or settlement of outstanding Awards mentioned above; and • no exercise of the outstanding warrants mentioned above.

<div align='center'>S-4

RISK FACTORS</div>

You should consider carefully the risks described below and discussed under the section captioned “Risk Factors” contained in our Annual Report on Form 10-K for the year ended June 30, 2024, and as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended, or the Exchange Act, including our Quarterly Reports on Form 10-Q for the periods ended September 30, 2024, December 31, 2024 and March 31, 2025, which are incorporated by reference in this prospectus supplement and the accompanying prospectus in their entirety, together with other information in this prospectus supplement, the accompanying prospectus and the information and documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in